4basebio (LON:4BB) Shares Down 2.1% – Should You Sell?

4basebio PLC (LON:4BB) dropped 2.1% during trading on Thursday . The company traded as low as GBX 1,185 ($14.72) and last traded at GBX 1,185 ($14.72). Approximately 3,034 shares traded hands during trading, a decline of 31% from the average daily volume of 4,379 shares. The stock had previously closed at GBX 1,210 ($15.03).

4basebio Stock Down 3.3 %

The business’s 50 day moving average price is GBX 1,247.97 and its 200 day moving average price is GBX 1,375.28. The firm has a market cap of £149.88 million, a price-to-earnings ratio of -1,500.00 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73.

Insiders Place Their Bets

In other 4basebio news, insider Heikki Lanckriet acquired 46,500 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was acquired at an average cost of GBX 1,325 ($16.46) per share, for a total transaction of £616,125 ($765,372.67). Insiders own 68.44% of the company’s stock.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.